4.7 Review

Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification

Journal

ANNALS OF ONCOLOGY
Volume 28, Issue 9, Pages 2067-2076

Publisher

ELSEVIER
DOI: 10.1093/annonc/mdx180

Keywords

pancreatic adenocarcinoma; borderline resectable; neoadjuvant therapy; staging criteria; CT

Categories

Funding

  1. Hale Center for Pancreatic Cancer Research, NIH/NCI [U01 CA210171]
  2. Department of Defense [CA130288]
  3. Lustgarten Foundation
  4. Pancreatic Cancer Action Network
  5. Noble Effort Fund
  6. Peter R. Leavitt Family Fund
  7. Wexler Family Fund
  8. Promises for Purple

Ask authors/readers for more resources

Background: Diagnostic imaging plays a critical role in the initial diagnosis and therapeutic monitoring of pancreatic adenocarcinoma. Over the past decade, the concept of 'borderline resectable' pancreatic cancer has emerged to describe a distinct subset of patients existing along the spectrum from resectable to locally advanced disease for whom a microscopically margin-positive (R1) resection is considered relatively more likely, primarily due to the relationship of the primary tumor with surrounding vasculature. Materials and methods: This review traces the conceptual evolution of borderline resectability from a radiological perspective, including the debates over the key imaging criteria that define the thresholds between resectable, borderline resectable, and locally advanced or metastatic disease. This review also addresses the data supporting neoadjuvant therapy in this population and discusses current imaging practices before and during treatment. Results: A growing body of evidence suggests that the borderline resectable group of patients may particularly benefit from neoadjuvant therapy to increase the likelihood of an ultimately margin-negative (R0) resection. Unfortunately, anatomic and imaging criteria to define borderline resectability are not yet universally agreed upon, with several classification systems proposed in the literature and considerable variance in institution-by-institution practice. As a result of this lack of consensus, as well as overall small patient numbers and lack of established clinical trials dedicated to borderline resectable patients, accurate evidence-based diagnostic categorization and treatment selection for this subset of patients remains a significant challenge. Conclusions: Clinicians and radiologists alike should be cognizant of evolving imaging criteria for borderline resectability given their profound implications for treatment strategy, follow-up recommendations, and prognosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available